News
Mounting concerns that FDA reviewers could start missing PDUFA deadlines have put many on edge. The moment calls for ...
Cancer drugs that received accelerated approval from the FDA gained regular approval significantly faster if their ...
Two former FDA leaders look at Commissioner Marty Makary’s early stumbles — and lay out a list of priorities to protect both ...
After mass layoffs, the FDA has started missing certain deadlines, pushing one biopharma to delay a phase 3 trial and ...
4d
Pharmaceutical Technology on MSNFDA layoffs and priority review programme’s lapse disrupt rare disease pipelineThe expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug ...
Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the ...
Vanda Pharmaceuticals is suing the FDA again, this time alleging the agency is unlawfully delaying a hearing to discuss the ...
On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...
Donald Trump takes biopharma on a tariff-themed rollercoaster ride; J&J kicks off the Q1 earnings season; experts express ...
Significant proposed regulatory changes within the U.S. Food and Drug Administration (FDA), along with large layoffs that ...
"Currently, there is no FDA-approved topical formulation of finasteride," it continued. "Compounded topical finasteride products do not have FDA-approved labeling. There are potential serious ...
U.S. Food and Drug Administration Commissioner Martin Makary announced on Thursday a policy to limit employees of companies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results